Sorrento’s Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China

 Sorrento’s Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China

Sorrento’s Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China

Shots:

  • Mabpharm files Infliximab Biosimilar’s NDA to the NMPA based on the trial evaluating Infliximab Biosimilar vs Infliximab and has used CHO expression system which resulted in safety results and lower immunogenicity
  • Sorrento plans to file BLA for Infliximab Biosimilar in the US by the end of 2020. Sorrento signed a worldwide license agreement with Mabpharm, and has global rights to Mabpharm Infliximab biobetter Ab outside of China
  • Remicade (Infliximab) is a mAb works as a tumor necrosis factor inhibitors (TNFs) targeted for RA, CD, UC, AS (a type of spinal arthritis), PsA, and the red, scaly skin patches of plaque psoriasis. Sorrento is also developing Resiniferatoxin (“RTX”) a P-Ib candidate for terminal cancer and osteoarthritis patients

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post